PD-1抑制剂retifanlimab在复发性微卫星高度不稳定或错配修复缺陷子宫内膜癌患者中的抗肿瘤活性与安全性:POD1UM-101 I期研究H队列的最终安全性和有效性结果
POD1UM-101 I期研究H队列报告retifanlimab治疗复发性MSI-H/dMMR子宫内膜癌的最终结果,76例患者接受retifanlimab 500 mg每4周静脉给药,主要终点为安全性/耐受性。客观缓解率51.3%(95% CI 39.6-63.0%),中位无进展生存期12.2个月,中位随访26.0个月时中位缓解持续时间未达到,总体耐受性良好。
要点
- 76例复发性MSI-H/dMMR子宫内膜癌患者接受retifanlimab 500 mg每4周静脉给药,最长2年。
- 客观缓解率51.3%(95% CI 39.6-63.0%),完全缓解25.0%,部分缓解26.3%。
- 中位无进展生存期12.2个月,中位随访26.0个月时中位缓解持续时间未达到。
核心结论
- Retifanlimab总体耐受性良好,在经治复发性MSI-H/dMMR子宫内膜癌患者中显示出令人鼓舞的抗肿瘤活性。
研究设计与样本
- POD1UM-101 I期研究扩展队列H,纳入≥18岁、组织学证实不可切除或复发性MSI-H/dMMR子宫内膜癌、未接受过检查点抑制剂治疗的患者。
- 患者接受retifanlimab 500 mg静脉给药,每4周一次,最长2年;主要终点为安全性/耐受性。
- 数据截止2023年5月17日,76例患者至少接受一剂retifanlimab。
主要发现
- 中位(范围)年龄67(49-88)岁;88.2%患者为复发性转移性疾病,80.3%有内脏转移。
- 75例(98.7%)接受过至少一种既往全身治疗;中位retifanlimab暴露10.0(0.03-25.9)个月,23例完成治疗。
- 38例(50.0%)发生≥3级治疗中出现的不良事件(TEAE),最常见为贫血(n=10[13.2%])。
- 63例(82.9%)发生治疗相关不良事件(TRAE;≥3级n=14[18.4%]),最常见为乏力(n=14[18.4%]);2例发生导致死亡的TEAE,无致命性TRAE。
- 39例客观缓解(51.3%;95% CI 39.6-63.0%),其中完全缓解19例(25.0%)、部分缓解20例(26.3%);中位无进展生存期12.2个月,30例(76.9%)缓解持续时间≥12个月,中位随访26.0个月时中位缓解持续时间未达到。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Retifanlimab is a humanized immunoglobulin G4 monoclonal antibody against programmed death 1 being investigated in several solid tumor types. We report final results from patients with recurrent microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) endometrial cancer treated with retifanlimab in a POD1UM-101 expansion cohort. METHODS: Eligible patients (≥18 years; histologically proven/unresectable/recurrent, MSI-H/dMMR endometrial cancer; checkpoint inhibitor naive) received retifanlimab 500 mg intravenously every 4 weeks for ≤2 years. Primary endpoint was safety/tolerability. RESULTS: At data cutoff (May 17, 2023), 76 patients had received at least one retifanlimab dose. Median (range) age was 67 (49-88) years; 88.2% of patients had recurrent metastatic disease and 80.3% had visceral metastases. Seventy-five patients (98.7%) had received at least one prior systemic therapy. Median retifanlimab exposure was 10.0 (0.03-25.9) months; 23 patients completed treatment. 38 patients (50.0%) had grade ≥3 treatment-emergent adverse events (TEAEs), most commonly anemia (n = 10 [13.2%]). 63 patients (82.9%) had treatment-related AEs (TRAEs; grade ≥3, n = 14 [18.4%]); most common was fatigue (n = 14 [18.4%]). Two patients had TEAEs that led to death; no TRAEs were fatal. 39 patients had objective responses (51.3%; 95% CI, 39.6-63.0%); 19 patients (25.0%) had complete response and 20 (26.3%) had partial response. Median progression-free survival was 12.2 months; 30 patients (76.9%) had duration of response (DOR) ≥12 months. Median DOR was not reached after median follow-up time of 26.0 months. CONCLUSIONS: Retifanlimab was generally well tolerated and demonstrated encouraging anti-tumor activity in patients with pre-treated recurrent MSI-H/dMMR endometrial cancer.
引用
- Berton D, Pautier P, Lorusso D, et al. Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study. Gynecol Oncol. 2024. PMID: 38824752. doi:10.1016/j.ygyno.2024.05.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。